Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Ne...

Full description

Bibliographic Details
Main Authors:	Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-05-01
Series:	Neuropsychiatric Disease and Treatment
Subjects:	number-needed-to-harm number-needed-to-treat paliperidone palmitate 3-monthly remission
Online Access:	https://www.dovepress.com/clinical-relevance-of-paliperidone-palmitate-3-monthly-in-treating-sch-peer-reviewed-article-NDT

Similar Items

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
by: Mathews M, et al.
Published: (2020-06-01)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
by: Rebekka Lencer, et al.
Published: (2021-05-01)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
by: García-Carmona JA, et al.
Published: (2023-09-01)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
by: S.L. Romero Guillena, et al.
Published: (2022-06-01)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
by: Giron‐Hernandez C, et al.
Published: (2023-04-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
by: P. Escobedo-Aedo, et al.
Published: (2022-06-01)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
by: Emsley R, et al.
Published: (2017-08-01)

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
by: Jie Liu, et al.
Published: (2022-02-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
by: Savitz AJ, et al.
Published: (2017-08-01)

The effectiveness of paliperidone palmitate at the stage of stabilizing treatment of schizophrenia in the outpatient department. Clinical observation
by: M. R. Bagautdinov
Published: (2020-01-01)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023-08-01)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li HF, et al.
Published: (2015-12-01)

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
by: Jeffrey P. Anderson, et al.
Published: (2017-10-01)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola Danielle, et al.
Published: (2012-03-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review
by: Qian Li, et al.
Published: (2024-01-01)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
by: Gattaz WF, et al.
Published: (2020-09-01)

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study
by: S. Vanzetto, et al.
Published: (2022-06-01)

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
by: Kanglai Li, et al.
Published: (2021-01-01)

Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal
by: João Marques-Teixeira, et al.
Published: (2022-11-01)

Clinical outcomes with paliperidone palmitate 3-monthly injection as monotherapy: observational 3-year follow-up of patients with schizophrenia
by: Ivana Clark, et al.
Published: (2024-01-01)

A case of tardive dyskinesia with paliperidone palmitate
by: Philip Kumar Boyanapally, et al.
Published: (2015-01-01)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
by: I.E. Menendez Gil, et al.
Published: (2022-06-01)

Paliperidon palmitata bağlı siyalore
by: Cengiz Cengisiz, et al.
Published: (2016-12-01)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
by: Charmi Patel, MPH, RN, et al.
Published: (2020-01-01)

One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives
by: Spoelstra SK, et al.
Published: (2022-03-01)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
by: Zhao M, et al.
Published: (2023-04-01)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
by: Sam Debaveye, et al.
Published: (2019-06-01)

Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
by: Turkoz I, et al.
Published: (2022-08-01)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
by: Zhao JP, et al.
Published: (2017-08-01)

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
by: Miquel Bioque, et al.
Published: (2020-01-01)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
by: M. Markovic
Published: (2022-06-01)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019-03-01)

Effect of paliperidone palmitate treatment on disease family burden and rehabilitation effect in community schizophrenic patients
by: GE Xiaolei, et al.
Published: (2023-07-01)